Overview

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis

Status:
Completed
Trial end date:
2013-12-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis (RA) subjects
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Treatments:
Peficitinib